Skip to main content
. Author manuscript; available in PMC: 2008 Oct 1.
Published in final edited form as: Cancer Cell. 2007 Oct;12(4):367–380. doi: 10.1016/j.ccr.2007.08.031

Figure 6. Kaplan-Meier survival plots of FLT3-ITD positive versus FLT3 wildtype (WT) patients with CMML.

Figure 6

Survival data available from 193 newly diagnosed patients with CMML at the MD Anderson Cancer Center (MDACC) were plotted, including FLT3-ITD positive (n=6) and FLT3-ITD negative (wildtype FLT3; n=187) patients. FLT3-ITD positive patients exhibited a median survival time of 8.5 months compared to 18.2 months for FLT3 wildtype CMML patients (p=0.09093; log-rank analysis). Median survival times and statistical analyses were calculated using STATISTICA data analysis software.